Evidence map›Paper›PMID 30683134›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

MicroRNA-29a activates a multi-component growth and invasion program in glioblastoma.

Yun Zhao, Wei Huang, Tae-Min Kim, Yuchae Jung, Lata G Menon, Hongyan Xing, Hongwei Li, Rona S Carroll, Peter J Park, Hong Wei Yang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Expression Patterns ofJournal of clinical medicine · 2020
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Yun ZhaoDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Wei HuangDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Tae-Min KimDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Yuchae JungDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Lata G MenonDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Hongyan XingDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Hongwei LiDepartment of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Rona S CarrollDepartment of Neurological Surgery, University of Massachusetts Medical School, Albert Sherman Center AS6-1001, 368 Plantation Street, Worcester, MA, 01605, USA.
Peter J ParkDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Hong Wei YangDepartment of Neurological Surgery, University of Massachusetts Medical School, Albert Sherman Center AS6-1001, 368 Plantation Street, Worcester, MA, 01605, USA. Hongwei.yang@umassmed.edu.
Mark D JohnsonDepartment of Neurological Surgery, University of Massachusetts Medical School, Albert Sherman Center AS6-1001, 368 Plantation Street, Worcester, MA, 01605, USA. mark.johnson3@umassmemorial.org.
Harvard University · USBrigham and Women's Hospital · USNeurological Surgery · USTumor Hospital of Guangxi Medical University · CNUMass Memorial Health Care · US

Funding

Genetics of Adult Idiopathic HydrocephalusR01NS106985 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MARK D JOHNSON · 2018 to 2026
$4.2M
MicroRNA Biogenesis and the Cancer ProteomeDP2OD002319 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, MARK D · 2007 to 2007
$2.6M
Preventing Glioma Cancer Stem Cell Dispersal Using Cdc2 Kinase InhibitorsR01NS062219 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, MARK D · 2010 to 2014
$1.8M
NIH HHS DP2 OD002319NIH HHS DP2OD002319NINDS NIH HHS R01 NS062219NINDS NIH HHS R01 NS106985
6 · The paper itself

Abstract

backgroundGlioblastoma is a malignant brain tumor characterized by rapid growth, diffuse invasion and therapeutic resistance. We recently used microRNA expression profiles to subclassify glioblastoma into five genetically and clinically distinct subclasses, and showed that microRNAs both define and contribute to the phenotypes of these subclasses. Here we show that miR-29a activates a multi-faceted growth and invasion program that promotes glioblastoma aggressiveness.

methodsmicroRNA expression profiles from 197 glioblastomas were analyzed to identify the candidate miRNAs that are correlated to glioblastoma aggressiveness. The candidate miRNA, miR-29a, was further studied in vitro and in vivo.

resultsMembers of the miR-29 subfamily display increased expression in the two glioblastoma subclasses with the worst prognoses (astrocytic and neural). We observed that miR-29a is among the microRNAs that are most positively-correlated with PTEN copy number in glioblastoma, and that miR-29a promotes glioblastoma growth and invasion in part by targeting PTEN. In PTEN-deficient glioblastoma cells, however, miR-29a nevertheless activates AKT by downregulating the metastasis suppressor, EphB3. In addition, miR-29a robustly promotes invasion in PTEN-deficient glioblastoma cells by repressing translation of the Sox4 transcription factor, and this upregulates the invasion-promoting protein, HIC5. Indeed, we identified Sox4 as the most anti-correlated predicted target of miR-29a in glioblastoma. Importantly, inhibition of endogenous miR-29a decreases glioblastoma growth and invasion in vitro and in vivo, and increased miR-29a expression in glioblastoma specimens correlates with decreased patient survival.

conclusionsTaken together, these data identify miR-29a as a master regulator of glioblastoma growth and invasion.

Indexed as

AnimalsCell Line, TumorCell ProliferationDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticGlioblastomaHumansMaleMiceMicroRNAsNeoplasm InvasivenessOncogene Protein v-aktPTEN PhosphohydrolaseXenograft Model Antitumor AssaysMicroRNAsMIRN29a microRNA, humanOncogene Protein v-aktPTEN PhosphohydrolasePTEN protein, humanGlioblastomaInvasionmiR-29aPTENSox4

Identifiers

PMID30683134
PMCPMC6347789
OpenAlexW2919217142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.